Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Vor BioPharma Inc (Vor Bio) is a clinical-stage biotechnology company developing the treatment of autoimmune diseases. The company’s pipeline products include TACI-Fc, a dual BAFF/APRIL inhibitor which treats myasthenia gravis, sjogren’s disease, systemic lupus erythematosus, rheumatoid arthritis, IgA nephropathy, neuromyelitis optica spectrum disorder, lupus nephritis, membranous nephritis and other indications. Vor Bio product delivers therapies that restore balance to the immune system. The company works in collaboration with other organizations for the development of its products. Vor Bio is headquartered in Boston, Massachusetts, the US.
Headquarters
United States of America
Address
500 Boylston Street, Suite 1350, Boston, Massachusetts, 02116
Website
www.vorbio.com
Telephone
1 617 6556580
No of Employees
76
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
VOR (NASD)
EPS
XYZ
Net Income (2024)
XYZ
-495.3%
(2024 vs 2023)
Market Cap*
$996.5M
* As of and is in US$
Vor BioPharma Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| TACI-Fc: |
| Myasthenia Gravis |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2022 | Official Trials/Tests | In December, the company announced initial clinical data from VBP101, its Phase 1/2a multicenter, open-label, first-in-human study of tremtelectogene empogeditemcel or trem-cel (formerly VOR33) in patients with acute myeloid leukemia (AML). |
| 2022 | Others | In October, the company announced data demonstrating the potential of the Company’s novel platform to use various base editing strategies. |
| 2022 | Corporate Changes/Expansions | In September, the company opened its new in-house clinical manufacturing facility in Cambridge, Massachusetts, the US. |
Competitor Comparison
| Key Parameters | Vor BioPharma Inc | Johnson & Johnson | Amgen Inc | Vertex Pharmaceuticals Inc | Argenx SE |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | Netherlands |
| City | Boston | New Brunswick | Thousand Oaks | Boston | Amsterdam |
| State/Province | Massachusetts | New Jersey | California | Massachusetts | Noord-Holland |
| No. of Employees | 76 | 138,200 | 31,500 | 6,400 | 1,863 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jean-Paul Kress, M.D | Chief Executive Officer; Chairman; President | Executive Board | 2025 | 60 |
| Sandesh Mahatme | Chief Financial Officer; Chief Business Officer | Senior Management | 2025 | 61 |
| Jeremy Sokolove, M.D. | Chief Medical Officer | Senior Management | 2025 | 52 |
| Dallan Murray | Chief Commercial Officer | Senior Management | - | - |
| Navid Z. Khan, PhD | Chief Medical Affairs Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer